TY  - JOUR
AU  - Provencio, Mariano
AU  - Serna-Blasco, Roberto
AU  - Franco, Fabio
AU  - Calvo, Virgina
AU  - Royuela, Ana
AU  - Auglytė, Milda
AU  - Sánchez-Hernández, Alfredo
AU  - de Julián Campayo, María
AU  - García-Girón, Carlos
AU  - Dómine, Manuel
AU  - Blasco, Ana
AU  - Sánchez, José M
AU  - Oramas, Juana
AU  - Bosch-Barrera, Joaquim
AU  - Sala, María Á
AU  - Sereno, María
AU  - Ortega, Ana L
AU  - Chara, Luis
AU  - Hernández, Berta
AU  - Padilla, Airam
AU  - Coves, Juan
AU  - Blanco, Remedios
AU  - Balsalobre, José
AU  - Mielgo, Xabier
AU  - Bueno, Coralia
AU  - Jantus-Lewintre, Eloisa
AU  - Molina-Vila, Miguel Á
AU  - Romero, Atocha
PY  - 2021
DO  - 10.1016/j.ejca.2021.02.031
UR  - http://hdl.handle.net/10668/17547
T2  - European journal of cancer (Oxford, England : 1990)
AB  - Survival data support the use of first-line osimertinib as the standard of care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). However, it remains unclear whether upfront osimertinib is superior to sequential...
LA  - en
KW  - EGFR
KW  - NSCLC
KW  - Osimertinib
KW  - TKI
KW  - ctDNA
KW  - Acrylamides
KW  - Aged
KW  - Aniline Compounds
KW  - Antineoplastic Agents
KW  - Biomarkers, Tumor
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Circulating Tumor DNA
KW  - Clinical Decision-Making
KW  - Cross-Sectional Studies
KW  - DNA Mutational Analysis
KW  - ErbB Receptors
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Mutation
KW  - Neoplasm Staging
KW  - Polymerase Chain Reaction
KW  - Predictive Value of Tests
KW  - Prospective Studies
KW  - Protein Kinase Inhibitors
KW  - Spain
KW  - Time Factors
KW  - Treatment Outcome
TI  - Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment.
TY  - research article
VL  - 149
ER  -